Table 2.
Utilization in the last 6 months | Utilization ever | |||
---|---|---|---|---|
Unadjusted model OR (95% CI) |
Adjusted model OR (95% CI) |
Unadjusted model OR (95% CI) |
Adjusted model OR (95% CI) |
|
Full Sample | ||||
Disease Activity (per unit increase in DAS28-CRP) | 1.07 (0.94, 1.22) | 1.01 (0.86, 1.19) | 1.04 (0.95, 1.14) | 1.03 (0.92, 1.16) |
Disability (per unit increase in HAQ) | 1.40 (1.12, 1.74) | 1.41 (1.05, 1.88) | 1.18 (1.01, 1.38) | 1.09 (0.89, 1.35) |
Age (per year) | 1.03 (1.02, 1.05) | 1.03 (1.01, 1.05) | 1.03 (1.02, 1.04) | 1.02 (1.01, 1.03) |
BMI (per 1kg/m2) | 1.02 (0.99, 1.04) | 1.02 (0.99, 1.04) | 1.02 (1.00, 1.03) | 1.02 (1.00, 1.03) |
Gender (Ref: Women) | 0.91 (0.70, 1.18) | 1.04 (0.78, 1.37) | 0.87 (0.73, 1.04) | 1.02 (0.83, 1.24) |
Disease duration (per year) | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.00) | 1.01 (1.00, 1.01) | 1.00 (1.00, 1.01) |
Comorbidities (per increase in number) | 1.18 (1.09, 1.27) | 1.07 (0.98, 1.17) | 1.30 (1.22, 1.39) | 1.20 (1.11, 1.29) |
DMARD use (Ref: yes) | 1.08 (0.86, 1.36) | 1.06 (0.83, 1.35) | 0.94 (0.80, 1.12) | 0.95 (0.79, 1.15) |
Household income (Ref: <$30k) | 1.02 (0.83, 1.24) | 1.19 (0.94, 1.50) | 0.97 (0.84, 1.12) | 1.14 (0.96, 1.36) |
Employed (Ref: no) | 1.39 (1.12, 1.73) | 1.18 (0.93, 1.52) | 1.41 (1.23, 1.63) | 1.21 (1.02, 1.43) |
Education (Ref: > HS) | 0.88 (0.74, 1.05) | 0.84 (0.69, 1.02) | 0.89 (0.79, 1.01) | 0.88 (0.76, 1.02) |
Early RA Subsample | ||||
Disease Activity (per unit increase in DAS28-CRP) | 1.08 (0.88, 1.31) | 1.11 (0.86, 1.43) | 1.06 (0.92, 1.22) | 1.10 (0.91, 1.33) |
Disability (per unit increase in HAQ) | 1.04 (0.75, 1.44) | 1.12 (0.71, 1.77) | 1.08 (0.85, 1.37) | 1.08 (0.78, 1.50) |
Age (per year) | 1.04 (1.02, 1.07) | 1.05 (1.02, 1.08) | 1.04 (1.02, 1.05) | 1.05 (1.03, 1.07) |
BMI (per 1kg/m2) | 1.01 (0.97, 1.05) | 1.02 (0.98, 1.06) | 1.02 (0.99, 1.04) | 1.01 (0.98, 1.04) |
Gender (Ref: Women) | 1.14 (0.78, 1.65) | 1.21 (0.80, 1.21) | 0.94 (0.71, 1.26) | 1.02 (0.74, 1.40) |
Disease duration (per year) | 0.96 (0.92, 1.01) | 0.97 (0.92, 1.01) | 1.03 (1.00, 1.07) | 1.04 (1.01, 1.08) |
Comorbidities (per increase in number) | 1.06 (0.91, 1.24) | 0.98 (0.82, 1.16) | 1.17 (1.04, 1.31) | 1.08 (0.95, 1.22) |
DMARD use (Ref: yes) | 0.85 (0.56, 1.28) | 0.80 (0.52, 1.23) | 0.76 (0.56, 1.02) | 0.72 (0.52, 0.99) |
Household income (Ref: <$30k) | 1.21 (0.89, 1.64) | 1.23 (0.83, 1.82) | 1.12 (0.89, 1.40) | 1.12 (0.85, 1.50) |
Employed (Ref: no) | 1.10 (0.81, 1.48) | 1.00 (0.69, 1.45) | 1.07 (0.86, 1.33) | 0.91 (0.70, 1.19) |
Education (Ref: > HS) | 0.80 (0.60, 1.07) | 0.76 (0.54, 1.08) | 0.81 (0.66, 1.00) | 0.76 (0.60, 0.98) |
Established RA Subsample | ||||
Disease Activity (per unit increase in DAS28-CRP) | 1.08 (0.90, 1.29) | 0.96 (0.77, 1.19) | 1.07 (0.94, 1.21) | 1.00 (0.85, 1.17) |
Disability (per unit increase in HAQ) | 1.93 (1.41, 2.66) | 1.70 (1.14, 2.52) | 1.46 (1.16, 1.82) | 1.14 (0.86, 1.52) |
Age (per year) | 1.02 (1.00, 1.04) | 1.02 (0.99, 1.04) | 1.02 (1.01, 1.03) | 1.00 (0.99, 1.02) |
BMI (per 1kg/m2) | 1.02 (0.99, 1.05) | 1.02 (0.99, 1.05) | 1.02 (1.00, 1.04) | 1.02 (0.99, 1.04) |
Gender (Ref: Women) | 0.76 (0.52, 1.11) | 0.86 (0.57, 1.29) | 0.86 (0.68, 1.09) | 1.01 (0.77, 1.31) |
Disease duration (per year) | 1.00 (1.00, 1.01) | 1.00 (1.00, 1.00) | 1.00 (1.00, 1.01) | 1.00 (1.00, 1.01) |
Comorbidities (per increase in number) | 1.22 (1.11, 1.34) | 1.11 (1.00, 1.24) | 1.34 (1.23, 1.45) | 1.26 (1.15, 1.38) |
DMARD use (Ref: yes) | 1.28 (0.96, 1.70) | 1.23 (0.91, 1.68) | 1.17 (0.93, 1.48) | 1.19 (0.92, 1.54) |
Household income (Ref: <$30k) | 0.91 (0.69, 1.21) | 1.11 (0.81, 1.51) | 0.95 (0.78, 1.15) | 1.14 (0.90, 1.44) |
Employed (Ref: no) | 1.73 (1.21, 2.48) | 1.43 (0.97, 2.10) | 1.54 (1.26, 1.88) | 1.40 (1.10, 1.77) |
Education (Ref: > HS) | 0.94 (0.75, 1.16) | 0.89 (0.69, 1.14) | 0.94 (0.80, 1.11) | 0.95 (0.78, 1.14) |
Abbreviations: BMI, body mass index; DAS28-CRP, Disease Activity Scale 28 with C-Reactive Protein; DMARD, disease-modifying anti-rheumatic drug; HAQ, Health Activity Questionnaire; HS, high school; Ref, reference